These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 12360566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC, Vassallo M, Ross IN.
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract] [Full Text] [Related]

  • 3. Binswanger's disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases.
    Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC.
    Mov Disord; 1995 Jul; 10(4):450-4. PubMed ID: 7565825
    [Abstract] [Full Text] [Related]

  • 4. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.
    Tan EK, Chan LL, Wong MC.
    Clin Neurol Neurosurg; 2003 Apr; 105(2):132-4. PubMed ID: 12691807
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA.
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [Abstract] [Full Text] [Related]

  • 10. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J.
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [Abstract] [Full Text] [Related]

  • 11. Levodopa in the early treatment of Parkinson's disease.
    Murata M.
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.
    Pahwa R, Lyons KE.
    Neurol Clin; 2004 Oct; 22(3 Suppl):S35-52. PubMed ID: 15501365
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy.
    Bhidayasiri R, Jitkritsadakul O, Boonrod N, Rerknimitr R.
    Clin Neurol Neurosurg; 2014 Jan; 116():1-3. PubMed ID: 24388506
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.